
Cystic fibrosis is a life-shortening autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Small-molecule modulators have substantially improved outcomes in patients with CFTR folding or gating defects. However, individuals carrying class I nonsense mutations or severe class V splicing variants often remain poorly responsive. In these genetic conditions, the main therapeutic limitation is quantitative: there is insufficient CFTR substrate for correctors or potentiators to act effectively. Antisense oligonucleotides (ASOs) are RNA-targeted agents that can increase the pool of CFTR transcripts available for translation by promoting splice correction, inducing exon skipping or selectively modulating nonsense-mediated messenger RNA decay. Although these mechanisms differ, they converge on a common goal: increasing CFTR expression to a functionally relevant and pharmacologically responsive range. This review proposes a threshold-based framework for ASO development in cystic fibrosis. Within this model, ASOs primarily increase CFTR quantity, whereas correctors, potentiators, stabilisers, enhancers and related small molecules improve CFTR quality by acting on folding, trafficking, gating, conductance or membrane stability. The therapeutic aim is not complete molecular normalisation, but functional sufficiency. By raising CFTR abundance above a minimal functional threshold, ASOs may prime selected class I and class V genotypes for subsequent pharmacological modulation and extend precision treatment to patients who currently remain outside the effective range of approved CFTR modulators.
Neutralizing anti-drug antibodies (ADAs) against enzyme replacement therapy (ERT) in Fabry disease (FD) are associated with disease progression despite therapy in affected male patients. The aim of this study was to assess the long-term effects of ADAs on clinical outcomes. We analyzed the long-term outcomes of ADA-positive (n = 24) and ADA-negative (n = 28) male patients under agalsidase alfa or beta. The assessment included Fabry-associated clinical events (FACEs), determination of cardiac and renal function, evaluation of FD-related symptoms, and the analysis of plasma globotriaosylsphingosine (lyso-Gb3) values. Median observation time was 10 years. ADA-positive and ADA-negative patients presented with comparable disease burden at baseline. Although there were no significant differences in the overall event rate of FACEs (p = 0.114), ADA-positive patients had an increased risk of ischemic cardiac events, an increase in interventricular septum thickness in diastole (median difference 0.25 mm per year; 95
The impact of biologic therapies (biologic disease-modifying antirheumatic drugs [bDMARD]) used in psoriasis (Pso), psoriatic arthritis (PsA), and other forms of spondyloarthritis (SpA) on the risk of major cardiovascular events (MACE) remains controversial. We aimed to assess the risk of MACE after initiation of a bDMARD among patients with Pso, PsA, or SpA, in a real-world clinical setting. We conducted a nationwide cohort study using the French National Health Data System (SNDS). Adults with Pso, PsA, or SpA who initiated a bDMARD (tumor necrosis factor inhibitors [TNFi]; interleukin [IL] inhibitors: IL-12/23i, IL-23i, IL-17i) between 1 July, 2016, and 31 July, 2023 were eligible for inclusion. The primary outcome was incident MACE, defined as cardiovascular death and/or hospitalization for acute myocardial infarction or ischemic stroke. Inverse probability-weighted Cox models were used to estimate weighted hazard ratios and their confidence intervals. Models were further adjusted for time-varying concomitant treatments, treatment indication, year of initiation, and prior non-steroidal anti-inflammatory drug use. An interaction term between bDMARD exposure and history of cardiovascular disease was included. A total of 72,291 patients were included (mean age 46.1 ± 14.2 years, 49.4
Mirikizumab was approved in China for the treatment of Crohn’s disease (CD) in 2026. This study evaluated the induction and long-term maintenance of continuous mirikizumab treatment for up to 152 weeks in Chinese patients with moderately to severely active CD. This was a post hoc, exploratory, and descriptive subpopulation analysis of Chinese patients from the VIVID program, where patients with moderately to severely active CD received intravenous (IV) mirikizumab induction followed by subcutaneous (SC) maintenance dosing. At week 52, endoscopic responders continued SC dosing, while non-responders received IV re-induction at VIVID-2 entry, then resumed SC dosing. Key efficacy endpoints included clinical response by Patient-Reported Outcome, endoscopic response, clinical remission, biomarkers, and quality-of-life-related endpoints. Safety was assessed through week 152 (starting from VIVID-1). In VIVID-1, 164 Chinese patients were randomized and received study treatment; 152 patients with simple endoscopic score for Crohn’s disease ≥ 7 (or ≥ 4 for isolated ileal disease) were included in the primary analysis set (PAS). Among the PAS population, 83, 40, and 29 patients received mirikizumab, ustekinumab, and placebo, respectively. At week 52, the mirikizumab-treated group achieved higher endoscopic response-composite (37.3
Two of the most significant challenges in transplantation medicine are human leukocyte antigen sensitization, which limits access to kidney transplantation for patients with end-stage kidney disease owing to the lack of effective desensitization strategies, and chronic active antibody-mediated rejection (cAMR), a major cause of allograft dysfunction and graft loss following transplantation. Despite its substantial clinical significance, there remains a lack of high-quality evidence and well-established therapeutic algorithms for the management of cAMR, while many patients continue to be excluded from kidney transplantation because of immunological barriers. Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a central role in both innate and adaptive immune responses. Beyond its immunological functions, IL-6 has been implicated in the pathogenesis of a wide range of conditions, including atherosclerotic cardiovascular disease, diabetes mellitus, and various neurological disorders. Consequently, targeting the IL-6/IL-6 receptor signaling pathway has emerged as a promising therapeutic strategy in transplantation medicine, particularly for desensitization protocols and the treatment of cAMR. However, the current evidence base is restricted to studies evaluating tocilizumab and clazakizumab, with clinical benefits remaining inconsistent across studies. Limited evidence is available regarding the desensitization effectiveness of tocilizumab monotherapy. In cAMR, the phase III IMAGINE trial found no improvement in kidney function with clazakizumab despite reduced C-reactive protein. Current evidence does not support a routine IL-6 pathway blockade in cAMR, while further studies are required to prove the potential benefits in desensitization. In this narrative review, we comprehensively examine the role of IL-6 in the pathophysiology of kidney transplantation and critically appraise the available clinical evidence regarding IL-6/IL-6R-targeted therapies for the management of human leukocyte antigen sensitization and cAMR.